贝尔纳卡桑抑制热致死:缓解急性肺损伤和多器官功能障碍的潜在策略

相关实验视频

Updated: Jul 15, 2026

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device

Published on: September 24, 2020

Arzu Güneş¹, Duygu Gürsoy Gürgen², Arife Ahsen Kaplan³

¹Istanbul Medipol University, International School of Medicine, Department of Histology and Embryology, Istanbul, Turkey; Health Science and Technologies Research Institute (SABITA), Istanbul Medipol University, Istanbul, Turkey.

|July 9, 2025

概括

贝尔纳卡桑是一种卡斯帕酶-1 抑制剂,在急性肺损伤 (ALI) 的小鼠模型中减少了热和器官损伤. 这表明贝尔纳卡桑可能是预防ALI多器官功能障碍的潜在治疗方法.

科学领域:

肺部医学肺部医学
炎症研究炎症研究
药物发现药物发现药物发现

背景情况:

急性肺损伤 (ALI) 是一种严重的疾病,通常是由感染或创伤引起的.
炎症性细胞死亡的一种形式,由酶-1和IL-1β介导的炎症性细胞死亡,促使ALI的发病.
向热致死是一种潜在的ALI治疗策略.

研究的目的:

为了评估贝尔纳卡桑 (Bel) 的治疗疗效,一种卡斯巴酶-1 抑制剂,在ALI的脂聚糖 (LPS) 诱导的小鼠模型中.
评估贝尔纳卡桑能够抑制热和减轻多器官衰竭的能力.

主要方法:

BALB/c小鼠接受了LPS挑战,并接受了贝尔纳卡桑治疗.
在肺组织上进行了组织病理学,免疫组织化学和超结构分析.
评估了器官损伤,炎症 (CRP),IL-1β水平和巨细胞活动.

主要成果:

贝尔纳卡桑治疗减少了器官损伤标志物 (ALT,AST,BUN,肌) 和改善了组织形态.
贝尔纳卡桑抑制了IL-1β水平,并减少了 pyroptotic 和非 pyroptotic 膜巨细胞.
在belnacasan治疗时观察到血液空气屏障的完整性得到保护.

结论:

贝尔纳卡桑有效抑制热和减少ALI中的炎症.
卡斯巴酶-1 抑制剂可以保护器官形态,并防止多器官功能障碍.
贝尔纳卡桑在治疗ALI方面具有显著的治疗潜力.

关键词:

急性肺损伤,贝尔纳卡萨萨纳膜体巨细胞的巨细胞炎症炎症是一种炎症.热灭菌的发生.

更多相关视频

Noninvasive Intratracheal Lipopolysaccharide Instillation in Mice

Noninvasive Intratracheal Lipopolysaccharide Instillation in Mice

Published on: March 31, 2023

Author Spotlight: THP-1 Macrophage Response to LPS/ATP — Unveiling the Pyroptosis, Apoptosis, and Necroptosis Spectrum

Author Spotlight: THP-1 Macrophage Response to LPS/ATP — Unveiling the Pyroptosis, Apoptosis, and Necroptosis Spectrum

Published on: May 3, 2024

相关概念视频

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Acute Respiratory Failure-V

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...

Pharmaceutical Poisoning: Treatment Strategies

Pharmaceutical Poisoning: Treatment Strategies

Treatment strategies for poisoning are a critical aspect of emergency medicine, focusing on preventing the absorption of toxins and enhancing their elimination. When a poisoning incident occurs, the first response is to halt exposure and decontaminate the patient, particularly through gastrointestinal (GI) methods if the poison was ingested.Gastrointestinal Decontamination Techniques:Activated charcoal is the cornerstone of GI decontamination. It works through adsorption, binding the toxin to...

Myocarditis III: Medical Management

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...

Cardiopulmonary Resuscitation IV: Pharmacological Management

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...